Romina Lomonaco

5.5k total citations · 5 hit papers
37 papers, 4.2k citations indexed

About

Romina Lomonaco is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Romina Lomonaco has authored 37 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Epidemiology, 21 papers in Endocrinology, Diabetes and Metabolism and 14 papers in Hepatology. Recurrent topics in Romina Lomonaco's work include Liver Disease Diagnosis and Treatment (34 papers), Diet, Metabolism, and Disease (19 papers) and Liver Disease and Transplantation (9 papers). Romina Lomonaco is often cited by papers focused on Liver Disease Diagnosis and Treatment (34 papers), Diet, Metabolism, and Disease (19 papers) and Liver Disease and Transplantation (9 papers). Romina Lomonaco collaborates with scholars based in United States, France and Netherlands. Romina Lomonaco's co-authors include Kenneth Cusi, Fernando Bril, Beverly Orsak, Fermin O. Tio, Carolina Ortiz‐Lopez, Amy Webb, Joan Hecht, Paola Portillo-Sánchez, Jean Hardies and Diane Biernacki and has published in prestigious journals such as Annals of Internal Medicine, Hepatology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Romina Lomonaco

37 papers receiving 4.1k citations

Hit Papers

Long-Term Pioglitazone Treatment for Patients With Nonalc... 2015 2026 2018 2022 2016 2015 2019 2020 2025 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
    2016 737 citations Kenneth Cusi, Beverly Orsak et al. Annals of Internal Medicine profile →
  2. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
    2015 393 citations Paola Portillo-Sánchez, Fernando Bril et al. The Journal of Clinical Endocrinology & Metabolism profile →
  3. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
    2019 235 citations Fernando Bril, Diane Biernacki et al. Diabetes Care profile →
  4. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
    2020 231 citations Romina Lomonaco, Eddison Godinez Leiva et al. Diabetes Care profile →
  5. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
    2025 32 citations Diana Barb, Srilaxmi Kalavalapalli et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Romina Lomonaco United States 25 3.6k 2.2k 1.1k 734 710 37 4.2k
Fabio Nascimbeni Italy 28 4.1k 1.1× 2.2k 1.0× 1.5k 1.3× 563 0.8× 594 0.8× 54 4.8k
M. Marietti Italy 8 4.0k 1.1× 1.6k 0.7× 1.5k 1.3× 595 0.8× 975 1.4× 17 4.6k
Aynur Ünalp United States 17 4.1k 1.1× 2.1k 0.9× 1.7k 1.5× 673 0.9× 702 1.0× 32 4.6k
Beverly Orsak United States 16 2.8k 0.8× 1.8k 0.8× 905 0.8× 556 0.8× 546 0.8× 20 3.2k
Fernando Bril United States 33 4.8k 1.3× 2.9k 1.3× 1.5k 1.3× 961 1.3× 1.1k 1.5× 85 5.6k
Claire Z. Larter Australia 18 3.1k 0.8× 1.3k 0.6× 937 0.8× 595 0.8× 823 1.2× 24 3.7k
Carol Sargeant United States 12 3.5k 1.0× 1.7k 0.7× 1.5k 1.3× 851 1.2× 728 1.0× 17 4.2k
Etsuko Hashimoto Japan 35 4.4k 1.2× 1.8k 0.8× 2.3k 2.0× 771 1.1× 681 1.0× 107 5.2k
Stefania Natale Italy 5 4.5k 1.2× 2.6k 1.2× 1.0k 0.9× 756 1.0× 810 1.1× 8 5.1k
Luis Calzadilla Bertot Australia 16 3.2k 0.9× 1.5k 0.7× 1.6k 1.4× 564 0.8× 378 0.5× 38 3.6k

Countries citing papers authored by Romina Lomonaco

Since Specialization
Citations

This map shows the geographic impact of Romina Lomonaco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Romina Lomonaco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Romina Lomonaco more than expected).

Fields of papers citing papers by Romina Lomonaco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Romina Lomonaco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Romina Lomonaco. The network helps show where Romina Lomonaco may publish in the future.

Co-authorship network of co-authors of Romina Lomonaco

This figure shows the co-authorship network connecting the top 25 collaborators of Romina Lomonaco. A scholar is included among the top collaborators of Romina Lomonaco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Romina Lomonaco. Romina Lomonaco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kalavalapalli, Srilaxmi, et al.. (2026). Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 1 indexed citations
2.
Sharma, Anu, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.. (2025). Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment. Journal of the Endocrine Society. 10(1). bvaf209–bvaf209. 1 indexed citations
3.
Barb, Diana, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.. (2025). Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of Hepatology. 82(6). 979–991. 32 indexed citations breakdown →
4.
Sharma, Anu, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.. (2024). Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen. Obesity. 32(10). 1967–1974. 9 indexed citations
5.
Bril, Fernando, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.. (2024). Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants. JHEP Reports. 6(7). 101092–101092. 17 indexed citations
6.
Belfort‐DeAguiar, Renata, Romina Lomonaco, & Kenneth Cusi. (2022). Approach to the Patient With Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism. 108(2). 483–495. 10 indexed citations
7.
Bril, Fernando, Michael J. McPhaul, Srilaxmi Kalavalapalli, et al.. (2021). Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. The Journal of Clinical Endocrinology & Metabolism. 106(11). e4360–e4371. 11 indexed citations
8.
Lomonaco, Romina, Eddison Godinez Leiva, Fernando Bril, et al.. (2020). Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care. 44(2). 399–406. 231 indexed citations breakdown →
9.
Lomonaco, Romina, Nada Fanous, Srilaxmi Kalavalapalli, et al.. (2020). 1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes. 69(Supplement_1). 1 indexed citations
10.
Bril, Fernando, Diane Biernacki, Srilaxmi Kalavalapalli, et al.. (2019). Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 42(8). 1481–1488. 235 indexed citations breakdown →
11.
Bril, Fernando, Diana Barb, Romina Lomonaco, Jinping Lai, & Kenneth Cusi. (2019). Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. Journal of Hepatology. 72(3). 401–410. 42 indexed citations
12.
Bril, Fernando, Diane Biernacki, Romina Lomonaco, et al.. (2018). Role of Vitamin E for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients with T2DM—A Randomized, Controlled Trial. Diabetes. 67(Supplement_1). 3 indexed citations
13.
Bril, Fernando, Srilaxmi Kalavalapalli, Virginia Clark, et al.. (2017). Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clinical Gastroenterology and Hepatology. 16(4). 558–566.e2. 158 indexed citations
14.
Bril, Fernando, Romina Lomonaco, Beverly Orsak, et al.. (2017). Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. 102(8). 2950–2961. 75 indexed citations
15.
Cusi, Kenneth, Beverly Orsak, Fernando Bril, et al.. (2016). Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Annals of Internal Medicine. 14 indexed citations
16.
Bril, Fernando, Nishanth E. Sunny, Diane Biernacki, et al.. (2016). Plasma Thyroid Hormone Concentration is Associated with Hepatic Triglyceride Content in Patients with Type 2 Diabetes. Journal of Investigative Medicine. 64(1). 63–68. 24 indexed citations
17.
Bril, Fernando, John J. Sninsky, Arthur M. Baca, et al.. (2015). Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. The Journal of Clinical Endocrinology & Metabolism. 101(2). 644–652. 136 indexed citations
18.
Lomonaco, Romina, Carolina Ortiz‐Lopez, Beverly Orsak, et al.. (2011). Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 54(3). 837–845. 67 indexed citations
19.
Lomonaco, Romina, Janet Chen, & Kenneth Cusi. (2011). An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism. 2(5). 211–225. 30 indexed citations
20.
Lomonaco, Romina, Carolina Ortiz‐Lopez, Beverly Orsak, et al.. (2011). Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 55(5). 1389–1397. 356 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabio Nascimbeni Breakdown of academic impact, for papers by M. Marietti Breakdown of academic impact, for papers by Aynur Ünalp Breakdown of academic impact, for papers by Beverly Orsak Breakdown of academic impact, for papers by Fernando Bril Breakdown of academic impact, for papers by Claire Z. Larter Breakdown of academic impact, for papers by Carol Sargeant Breakdown of academic impact, for papers by Etsuko Hashimoto Breakdown of academic impact, for papers by Stefania Natale Breakdown of academic impact, for papers by Luis Calzadilla Bertot
Rankless by CCL
2026